SV Biotech Crossover Opportunities Fund LP — Form D
SV Biotech Crossover Opportunities Fund LP of LONDON, X0, a pooled investment fund, filed a Form D exempt-offering notice with the SEC on 2022-01-18. The offering totals $350.0M, of which $135.2M was reported sold. Industry: Pooled Investment Fund.
Offering
- Filed: 2022-01-18
- Form: D
- Accession: 0001903934-22-000001
- Industry: Pooled Investment Fund
- Exemptions: 06b, 3C, 3C.7
- Total offering: $350.0M
- Amount sold: $135.2M
- Remaining: $214.8M
- Investors: 7
- Date of first sale: 2021-12-31
- Security types: equity, fund interests
- Revenue range: Decline to Disclose
- SEC file number: 021-429725
Issuer
- Name: SV Biotech Crossover Opportunities Fund LP
- CIK: 0001903934
- Entity type: Limited Partnership
- Jurisdiction: UNITED KINGDOM
- Incorporated: 2021
- Address: 71 KINGSWAY, LONDON, X0, WC2B 6ST
- Phone: 44 20 7421 7081
Officers, directors & promoters (6)
| Name | Role | Location |
|---|
| N/A SV BCO I GP LLP | Director | London, X0 |
| Houman Ashrafian | Executive Officer | London, X0 |
| Kate Bingham | Executive Officer | London, X0 |
| N/A SV BCO I GP LLP | Executive Officer | London, X0 |
| Nicola Trbovic | Executive Officer | London, X0 |
| N/A SV Health Managers LLP | Promoter | London, X0 |
More